WellPoint Plans To Seek Pharma Partners For Outcomes-Based Contracting: An Interview With WellPoint's Brian Sweet
Executive Summary
In an interview, "The Pink Sheet" talked to WellPoint Chief Pharmacy Officer Brian Sweet about the near-to-mid-term outlook for outcomes-based agreements between payers and drug manufacturers, including initiatives WellPoint is taking to work differently with biopharma (1"The Pink Sheet," May 24, 2010)
You may also be interested in...
Anthem Adds Lilly To Its Real-World Drug Outcomes Research Collaborations
The firms are still working to determine specific drugs or disease states to be studied under a five-year agreement. Speeding research dissemination may also be addressed.
HealthCore And AstraZeneca Big Data Initiative Pushes Ahead, But Will Lack of Trust Deter Additional Partners?
AstraZeneca and HealthCore, a subsidiary of Wellpoint, are halfway through a four-year agreement to study the effectiveness and economics of marketed drugs using real world evidence. The collaboration is making progress, but reaching some goals has been a challenge, says HealthCore CEO Marcus Wilson
ACOs Get In Gear, Accelerating Biopharma’s Value Imperative
Pharmaceutical companies have been reluctant to discuss their accountable care organization strategies, but the 32 “Pioneer” ACOs created this year could impact the way pharma develops and commercializes its drugs, and their influence will be felt well beyond their current Medicare remit.